Richard S. Priestley
A potential role for cannabinoid receptors in the therapeutic action of fenofibrate
Priestley, Richard S.; Nickolls, Sarah A.; Alexander, Stephen P. H.; Kendall, David A.
Authors
Sarah A. Nickolls
Dr Steve Alexander steve.alexander@nottingham.ac.uk
ASSOCIATE PROFESSOR
David A. Kendall
Abstract
Cannabinoids are reported to have actions through peroxisome proliferator-activated receptors (PPARs), which led us to investigate PPAR agonists for activity at the cannabinoid receptors. Radio-ligand binding and functional assays were conducted using human recombinant cannabinoid type 1 (CB1) or cannabinoid type 2 (CB2) receptors, as well as the guinea pig isolated ileum, using the full agonist CP55940 as a positive control. The PPAR-alpha agonist fenofibrate exhibited submicromolar affinity for both receptors (pKi CB1, 6.3 +/- 0.1; CB2, 7.7 +/- 0.1). Functionally, fenofibrate acted as an agonist at the CB2 receptor (pEC50, 7.7 +/- 0.1) and a partial agonist at the CB1 receptor, although with a decrease in functional response at higher concentrations, producing bell-shaped concentration-response curves. High concentrations of fenofibrate were able to increase the dissociation rate constant for [(3)H]-CP55940 at the CB1 receptor, (kfast without: 1.2 +/- 0.2/min; with: 3.8 +/- 0.1 x 10(-2)/min) and decrease the maximal response to CP55940 (Rmax, 86 +/- 2%), which is consistent with a negative allosteric modulator. Fenofibrate also reduced electrically induced contractions in isolated guinea pig ileum via CB1 receptors (pEC50, 6.0 +/- 0.4). Fenofibrate is thus identified as an example of a new class of cannabinoid receptor ligand and allosteric modulator, with the potential to interact therapeutically with cannabinoid receptors in addition to its primary PPAR target.
Citation
Priestley, R. S., Nickolls, S. A., Alexander, S. P. H., & Kendall, D. A. (2015). A potential role for cannabinoid receptors in the therapeutic action of fenofibrate. FASEB Journal, 29(4), 1446-1455. https://doi.org/10.1096/fj.14-263053
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 1, 2014 |
Online Publication Date | Dec 30, 2014 |
Publication Date | Apr 1, 2015 |
Deposit Date | Aug 2, 2018 |
Journal | The FASEB Journal |
Print ISSN | 0892-6638 |
Electronic ISSN | 1530-6860 |
Publisher | Federation of American Society of Experimental Biology (FASEB) |
Peer Reviewed | Peer Reviewed |
Volume | 29 |
Issue | 4 |
Pages | 1446-1455 |
DOI | https://doi.org/10.1096/fj.14-263053 |
Public URL | https://nottingham-repository.worktribe.com/output/915582 |
Publisher URL | https://www.fasebj.org/doi/10.1096/fj.14-263053 |
You might also like
Natural product pharmacology: the British Journal of Pharmacology perspective
(2024)
Journal Article
Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review
(2024)
Journal Article
The IUPHAR/BPS Guide to PHARMACOLOGY in 2024
(2023)
Journal Article
Looking Under the Lamppost: The Search for New Cancer Targets in the Human Kinome
(2022)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search